Guo, C-G;
Chen, L;
Chan, EW;
Cheung, KS;
Isshiki, T;
Wong, ICK;
Leung, WK;
(2019)
Systematic Review with Meta-analysis: The Risk of Gastrointestinal Bleeding in Patients Taking Third-Generation P2Y12 Inhibitors Compared with Clopidogrel.
Alimentary Pharmacology and Therapeutics
, 49
(1)
pp. 7-19.
10.1111/apt.15059.
Preview |
Text
Wong_meta-analysis R1 13102018.pdf - Accepted Version Download (848kB) | Preview |
Abstract
BACKGROUND: Ticagrelor and prasugrel are third‐generation oral P2Y12 receptor antagonists with rapid onset and pronounced platelet inhibition. However, higher overall bleeding rates have been reported for these agents when compared with clopidogrel. // AIM: To compare the risk of gastrointestinal bleeding (GIB) among users of third‐generation P2Y12 inhibitors with clopidogrel. // METHODS: We systematically searched for published randomised controlled trials of ticagrelor or prasugrel versus clopidogrel until September 2018. The primary outcome was the risk of GIB among users of third‐generation P2Y12 inhibitors when compared to clopidogrel, expressed as risk ratio (RR) and 95% confidence interval (CI). The rates of non‐coronary artery bypass graft (CABG) major bleeding, life‐threatening bleeding, fatal bleeding, and intracranial bleeding were analysed as secondary outcomes. // RESULTS: Forty‐one studies were included in the analysis of non‐CABG major bleeding, of which 12 were included in the analysis of GIB including 58 678 patients. Third‐generation P2Y12 inhibitors were associated with higher risk of GIB as compared with clopidogrel (RR 1.28, 95% CI 1.13‐1.46). The findings were consistent for upper (RR 1.32, 95% CI 1.05‐1.67) and unspecified GIB (RR 1.25, 95% CI 1.01‐1.53), but not lower GIB (RR 1.25, 95% CI 0.95‐1.65). Subgroup analysis showed higher GIB risk in prasugrel studies (RR 1.40, 95% CI 1.10‐1.77) than in ticagrelor studies (RR 1.15, 95% CI 0.94‐1.39). Third‐generation P2Y12 inhibitors also increased the risk of non‐CABG major bleeding (RR 1.18, 95% CI 1.08‐1.28). // CONCLUSION: Third‐generation P2Y12 inhibitors were associated with increased risk of GIB and non‐CABG major bleeding when compared with clopidogrel.
| Type: | Article |
|---|---|
| Title: | Systematic Review with Meta-analysis: The Risk of Gastrointestinal Bleeding in Patients Taking Third-Generation P2Y12 Inhibitors Compared with Clopidogrel |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/apt.15059 |
| Publisher version: | https://doi.org/10.1111/apt.15059 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | ticagrelor, prasugrel, gastrointestinal bleeding, meta-analysis |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10060521 |
Archive Staff Only
 |
View Item |
